X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Ask About Adherence: OIG proposed rule to reform the rebate system could improve adherence

By Guest Contributor  |    May 15, 2019
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we are pleased to share a blog post from Leah L. Zullig, PhD.   Read More

New study finds hospitals continue to push patients to costlier outpatient settings

By Holly Campbell  |    May 13, 2019
A new study from the Health Care Cost Institute found that, for commercially insured patients, almost 50 percent of medicines administered by physicians, including treatments for diseases like...   Read More

4 Things to know about the IQVIA “Medicine Use and Spending” report

By Holly Campbell  |    May 9, 2019
Today, IQVIA released its Medicine Use and Spending in the U.S. – A Review of 2018 and Outlook to 2023 report – highlighting the drivers behind medicine price and spending trends, patient...   Read More

Meet MAT: 5 things to know about PhRMA’s new “Medicine Assistance Tool”

By Holly Campbell  |    May 9, 2019
Reinforcing our industry’s commitment to providing patients with more transparency about medicine costs, yesterday, our member companies announced the launch of the Medicine Assistance Tool, or MAT   Read More

The PBM story you haven’t heard: Hidden fees quadrupled in two years

By Robert Zirkelbach  |    March 20, 2019
In the ongoing conversation around the role of pharmacy benefit managers (PBMs) in the supply chain, a new report further illuminates incentives that tie PBM revenue to higher list prices for...   Read More

Health Affairs study misses the mark on medicine costs

By Holly Campbell  |    January 28, 2019
A recent study published in Health Affairs concludes that list price inflation for existing brand medicines is a key driver of rising medicine spending. However, by failing to account for the...   Read More

New government data show medicine price growth continues to decline

By Holly Campbell  |    January 18, 2019
Last year, the U.S. Food and Drug Administration approved a record 59 new treatments and cures. During this incredible period of innovation, medicine price growth continued to slow dramatically.   Read More

What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising

By Holly Campbell  |    October 15, 2018
Pharmaceutical Research and Manufacturers of America (PhRMA) member companies today announced their commitment to providing more transparency about medicine costs to help patients make more...   Read More

Americans want to know more than just the list price of a medicine—and we’re answering their call

By Robert Zirkelbach  |    October 15, 2018
The biopharmaceutical industry is answering the call to provide more information about medicine costs. As innovators of life-saving therapies, we recognize the importance of giving people the...   Read More

Coupons allow patients to remain on medicines in spite of high cost sharing and deductibles

By Katie Koziara  |    October 4, 2018
According to a new report by IQVIA Institute for Human Data Science, more and more patients are asked to pay high cost sharing due to changes in benefit design. Previous analysis has shown that...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates